May 30, 2014
Meiji Seika Pharma announced on May 27 that the atypical antipsychotic drug asenapine, which it is codeveloping with MSD K.K., significantly improved symptoms of schizophrenia compared to placebo in a multinational PIII clinical trial. The trial was conducted in Japan,...read more